查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1360316

細胞和基因治療製造品質控制 (QC) 市場（組成部分：設備和配件、消耗品等）- 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 202 Pages | 商品交期: 2-10個工作天內

價格

細胞和基因治療製造品質控制 (QC) 市場 - 報告範圍

TMR 關於全球細胞和基因治療製造品質控制 (QC) 市場的報告研究了過去和當前的成長趨勢以及機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供2017-2031年期間全球細胞和基因治療製造品質控制（QC）市場的收入，以2023年為基準年，2031年為預測年。該報告還提供了2023年至2031年全球細胞和基因治療製造品質控制（QC）市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解細胞和基因治療製造品質控制 (QC) 市場。

市場概況
2023年市場價值 3.717 億美元
2031 年市場價值 28億美元
年複合成長率 24.6%

該報告深入研究了全球細胞和基因治療製造品質控制（QC）市場的競爭格局。全球細胞和基因治療製造品質控制 (QC) 市場的主要參與者已被確定，並且每個參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球細胞和基因治療製造品質控制 (QC) 市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球細胞和基因治療製造品質控制 (QC) 市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 技術進步
  • 重要行業活動
  • 按地區/全球分類的監管情景
  • 主要研究機構參與
  • COVID-19 大流行對該行業的影響

第 6 章：全球分析與預測：按組成部分

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按組成部分，2017-2031
    • 設備及配件
    • 耗材
    • 其他
  • 市場吸引力分析：按組成部分

第 7 章：全球分析與預測：透過分析方法

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：2017-2031年分析法
    • 無菌檢測
    • 純度檢測
    • 效力測試
    • 身份測試
    • 其他
  • 市場吸引力分析：分析法

第 8 章：全球市場分析與預測：按流程

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依流程，2017-2031
    • 上游流程
    • 下游流程
    • 製程開發
  • 市場吸引力分析：按流程

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 製藥與生物技術公司
    • 合約製造組織 (CMO)
  • 市場吸引力分析：按最終用戶

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類，2022 年
  • 公司簡介
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • QIAGEN
    • Charles River Laboratories International, Inc.
    • Lonza Group AG
    • Merck KGaA
    • Intertek Group plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
Product Code: TMRGL85805

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing quality control (QC) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing quality control (QC) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing quality control (QC) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing quality control (QC) market.

Market Snapshot
Market Value in 2023US$ 371.7 Mn
Market Value in 2031US$ 2.8 Bn
CAGR24.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing quality control (QC) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing quality control (QC) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing quality control (QC) market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing quality control (QC) market. Key players operating in the global cell and gene therapy manufacturing quality control (QC) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing quality control (QC) market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Report:

  • What is the sales/revenue generated by cell and gene therapy manufacturing quality control (QC) across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing quality control (QC) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing quality control (QC) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing quality control (QC) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing quality control (QC) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. Major Research Institutes Involved
  • 5.5. COVID-19 Pandemic Impact on Industry

6. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Component

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Component, 2017-2031
    • 6.3.1. Equipment & Accessories
    • 6.3.2. Consumables
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Component

7. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Analytical Method

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 7.3.1. Sterility Testing
    • 7.3.2. Purity Testing
    • 7.3.3. Potency Testing
    • 7.3.4. Identity Testing
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Analytical Method

8. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Process

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Process, 2017-2031
    • 8.3.1. Upstream Processes
    • 8.3.2. Downstream Processes
    • 8.3.3. Process Development
  • 8.4. Market Attractiveness Analysis, by Process

9. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Pharmaceutical & Biotechnology Companies
    • 9.3.2. Contract Manufacturing Organizations (CMOs)
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Component, 2017-2031
    • 11.2.1. Equipment & Accessories
    • 11.2.2. Consumables
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 11.3.1. Sterility Testing
    • 11.3.2. Purity Testing
    • 11.3.3. Potency Testing
    • 11.3.4. Identity Testing
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Process, 2017-2031
    • 11.4.1. Upstream Processes
    • 11.4.2. Downstream Processes
    • 11.4.3. Process Development
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Pharmaceutical & Biotechnology Companies
    • 11.5.2. Contract Manufacturing Organizations (CMOs)
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Component
    • 11.7.2. By Analytical Method
    • 11.7.3. By Process
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Component, 2017-2031
    • 12.2.1. Equipment & Accessories
    • 12.2.2. Consumables
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 12.3.1. Sterility Testing
    • 12.3.2. Purity Testing
    • 12.3.3. Potency Testing
    • 12.3.4. Identity Testing
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Process, 2017-2031
    • 12.4.1. Upstream Processes
    • 12.4.2. Downstream Processes
    • 12.4.3. Process Development
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Pharmaceutical & Biotechnology Companies
    • 12.5.2. Contract Manufacturing Organizations (CMOs)
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Component
    • 12.7.2. By Analytical Method
    • 12.7.3. By Process
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Component, 2017-2031
    • 13.2.1. Equipment & Accessories
    • 13.2.2. Consumables
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 13.3.1. Sterility Testing
    • 13.3.2. Purity Testing
    • 13.3.3. Potency Testing
    • 13.3.4. Identity Testing
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Process, 2017-2031
    • 13.4.1. Upstream Processes
    • 13.4.2. Downstream Processes
    • 13.4.3. Process Development
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Pharmaceutical & Biotechnology Companies
    • 13.5.2. Contract Manufacturing Organizations (CMOs)
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Component
    • 13.7.2. By Analytical Method
    • 13.7.3. By Process
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Component, 2017-2031
    • 14.2.1. Equipment & Accessories
    • 14.2.2. Consumables
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 14.3.1. Sterility Testing
    • 14.3.2. Purity Testing
    • 14.3.3. Potency Testing
    • 14.3.4. Identity Testing
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Process, 2017-2031
    • 14.4.1. Upstream Processes
    • 14.4.2. Downstream Processes
    • 14.4.3. Process Development
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Pharmaceutical & Biotechnology Companies
    • 14.5.2. Contract Manufacturing Organizations (CMOs)
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Component
    • 14.7.2. By Analytical Method
    • 14.7.3. By Process
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Component, 2017-2031
    • 15.2.1. Equipment & Accessories
    • 15.2.2. Consumables
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 15.3.1. Sterility Testing
    • 15.3.2. Purity Testing
    • 15.3.3. Potency Testing
    • 15.3.4. Identity Testing
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Process , 2017-2031
    • 15.4.1. Upstream Processes
    • 15.4.2. Downstream Processes
    • 15.4.3. Process Development
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Pharmaceutical & Biotechnology Companies
    • 15.5.2. Contract Manufacturing Organizations (CMOs)
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Component
    • 15.7.2. By Analytical Method
    • 15.7.3. By Process
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. bioMerieux SA
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Bio-Rad Laboratories, Inc.
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Bio-Techne Corporation
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. QIAGEN
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Charles River Laboratories International, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Lonza Group AG
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Merck KGaA
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Intertek Group plc
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Thermo Fisher Scientific Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Eurofins Scientific S.E.
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. F. Hoffmann-La Roche Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments

List of Tables

  • Table 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 02: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 03: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 04: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 07: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 08: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 09: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 10: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 12: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 13: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 14: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 17: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 18: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 19: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 20: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 23: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 24: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 25: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 28: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 29: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 30: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Cell and Gene Therapy Manufacturing QC Market Value Share, by Component, 2022
  • Figure 03: Cell and Gene Therapy Manufacturing QC Market Value Share, by Product Type, 2022
  • Figure 04: Cell and Gene Therapy Manufacturing QC Market Value Share, by Process, 2022
  • Figure 05: Cell and Gene Therapy Manufacturing QC Market Value Share, by End-user, 2022
  • Figure 06: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 07: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component, 2023-2031
  • Figure 08: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Equipment & Accessories, 2017-2031
  • Figure 09: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Consumables, 2017-2031
  • Figure 10: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Others, 2017-2031
  • Figure 11: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 12: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 13: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Sterility Testing, 2017-2031
  • Figure 14: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Urological Surgery, 2017-2031
  • Figure 15: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Potency Testing, 2017-2031
  • Figure 16: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Identity Testing, 2017-2031
  • Figure 17: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 18: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 19: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Process, 2023-2031
  • Figure 20: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Upstream Processes, 2017-2031
  • Figure 21: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Downstream Processes, 2017-2031
  • Figure 22: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Process Development, 2017-2031
  • Figure 23: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 24: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 25: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 26: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Contract Manufacturing Organizations (CMOs), 2017-31
  • Figure 27: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 28: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 29: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 31: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 32: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 33: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 34: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 35: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 36: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 37: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 38: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 39: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 40: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 44: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 45: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 46: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 47: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 48: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 49: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 50: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 51: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 55: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 56: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 57: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 58: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 59: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 60: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 61: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 62: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 63: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 65: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 66: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 67: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 68: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 69: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 70: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 71: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 72: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 73: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 74: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 75: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 76: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 77: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 78: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 79: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 80: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 81: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 82: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 83: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031